Investment
Features
FeesSafety
Academy
More
Pluang+

Pacific Booker plans $10M private placement to fund Morrison project development.

Company Fundamentals
05 Oct 2026
Newsfile Corp
View Source
Neutral
Pacific Booker plans $10M private placement to fund Morrison project development.

Pacific Booker Minerals Inc. announced a non-brokered private placement to raise up to $10 million by selling 4,273,505 units at $2.34 each. Each unit includes one common share and one warrant to buy another share at $2.75 within 36 months. The funds will be used to advance the Morrison project and for general corporate purposes. The offering requires TSX Venture Exchange approval and includes a hold period and lock-up agreements for investors, including related parties participating under specific exemptions.

Pacific Booker Minerals Inc. announced a non-brokered private placement. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: Of 38 priced US stocks, 20 rose and 18 fell. Notable movers include DOW at USD 28.52 with a 1-day change of +1.95% and a typical hold time of 82 days, WPM at USD 136.00 with a +1.93% change and Pluang order activity of 36% Sell / 64% Buy, and KGC at USD 23.60 down -1.91% with 62% Sell / 38% Buy activity. The highest price among these is WPM at USD 136.00.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
Japan Gold Corp. to host live virtual update on Oct 6, showcasing exploration progress in Japan.

Japan Gold Corp. to host live virtual update on Oct 6, showcasing exploration progress in Japan.

Japan Gold Corp., the largest mineral exploration company in Japan, announced a live virtual corporate update on October 6, 2026, hosted by Red Cloud Financial Services. The event will include a presentation and live Q&A session, with a replay availa...

Market News
Neutral
4 hours ago
SPYM ETF charges less than VOO for S&P 500 exposure but tracks multiple indexes historically.

SPYM ETF charges less than VOO for S&P 500 exposure but tracks multiple indexes historically.

The SPDR Portfolio S&P 500 ETF (SPYM) charges a lower fee of 0.02% compared to Vanguard's VOO at 0.03%, making it slightly cheaper for investors seeking S&P 500 exposure. However, SPYM's long-term performance record is based on four different indexes...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App